Home Press Release Clinical Trial Logistics Market Size Projected to Reach $11.81 billion by 2034 | 9.3%

Clinical Trial Logistics Market Size Projected to Reach $11.81 billion by 2034 | 9.3%

23 Jul, 2026

According to Straits Research the global clinical trial logistics market size was valued at $5.32 billion in 2025 and is projected to grow from $5.79 billion in 2026 to $11.81 billion by 2034, registering a CAGR of 9.30% during the forecast period (2026–2034).

Market Dynamics

The clinical trial logistics market is driven by the expansion of global clinical programs that rely on coordinated distribution routes, controlled storage conditions, and structured shipment planning to support rising trial volumes across oncology, metabolic disorders, rare diseases, and advanced biological therapies. A key restraint for the market stems from the complexity of complying with varied regulatory procedures across countries, which introduces delays in customs clearance, documentation review, and temperature-controlled transport for sensitive investigational products. An opportunity emerges from the rapid development of regional depots, specialized storage hubs, and distribution centers that bring clinical materials closer to trial sites, enabling smoother site activation, faster resupply cycles, and broader participation in decentralized and hybrid study models.

North America currently dominates the global Clinical Trial Logistics Market due to its well-established pharmaceutical industry, advanced healthcare infrastructure, and large number of ongoing clinical trials. Asia-Pacific is expected to register the fastest growth during the forecast period, supported by increasing research activities, improving healthcare facilities, and rising investments from global pharmaceutical companies. Continuous expansion of cold-chain infrastructure and warehouse networks is further strengthening regional market growth.

Market Segments

  1. By Service (2026-2034)
    1. Transportation
      1. Road
      2. Air
      3. Others
    2. Warehousing & Distribution
    3. Value-Added Services (Labelling, Kitting, QP Release)
  2. By Clinical Phase  (2026-2034)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV / post-marketing
  3. By Therapeutic Area  (2026-2034)
    1. Oncology
    2. Cardiovascular Diseases
    3. Rare / Orphan Diseases
    4. Immunology & Inflammation
    5. Endocrine & Metabolic Disorders
    6. Neurology & Psychiatry
    7. Others
  4. By End-user  (2026-2034)
    1. Bio-Pharma Manufacturers
    2. CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
    3. Hospitals & Clinical-Trial Sites
    4. Other End Users
  5. By Temperature Range (2026-2034)
    1. Cold Chain
      1. Ambient (15-25 °C)
      2. Refrigerated (2–8 °C)
      3. Frozen (0 °C to -20 °C)
      4. Ultra-Cold / Cryogenic (-20 °C to -150 °C)
    2. Non Cold Chain